Skip to main content

Table 2 Hazard ratios for studied end points according to treatment at time of a study endpoint

From: Effects of oral glucose-lowering drugs on long term outcomes in patients with diabetes mellitus following myocardial infarction not treated with emergent percutaneous coronary intervention - a retrospective nationwide cohort study

Glucose-lowering drug

Cardiovascular mortality

Composite of cardiovascular

mortality and non-fatal MI

All-cause mortality

 

HR

95% CI

HR

95% CI

HR

95% CI

Metformin

1

 

1

 

1

 

Insulin

1.49

1.34-1.66

1.38

1.25-1.52

1.50

1.35-1.65

Glibenclamide

1.37

1.21-1.54

1.31

1.17-1.46

1.34

1.19-1.50

Glimepiride

1.32

1.17-1.48

1.19

1.06-1.32

1.30

1.16-1.45

Glipizide

1.33

1.16-1.52

1.25

1.11-1.42

1.30

1.14-1.48

Gliclazide

1.10

0.92-1.32

1.03

0.88-1.22

1.06

0.90-1.26

Tolbutamide

1.22

1.06-1.41

1.18

1.03-1.34

1.21

1.06-1.38

All sulfonylureas

1.28

1.14-1.44

1.20

1.08-1.33

1.25

1.13-1.40

  1. Hazard ratios (HRs) and 95% confidence intervals (CIs) for adverse cardiovascular end points according to glucose-lowering drug (monotherapy) at the time of a study endpoint. Time-dependent Cox analyses were performed with adjustments for age, sex, socioeconomic status, calendar year, concomitant pharmacotherapy, and comorbidity. MI = Myocardial infarction.
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840